Follow-up evaluation of a phase II prostate cancer vaccine trial.

Abstract

BACKGROUND:

A phase II trial, involving infusions of autologous dendritic cells (DC) and two human histocompatibility antigen (HLA-A2)-specific prostate-specific membrane antigen (PSMA) peptides, was recently completed. Thirty percent of the participants, including subjects with hormone-refractory metastastic disease, and those with suspected local recurrence of prostate cancer, were identified as clinical responders. This report describes the follow-up evaluation of 19 responders in the two study groups.

METHODS:

After conclusion of the study, study participants were subjected to follow-up evaluations at 6-8-week intervals. Each responder was reevaluated for response status, and duration of response was determined.

RESULTS:

Subjects were observed for an average of 291 days (metastastic group, group A-2) and 557 days (local recurrence group, group B), which included the treatment and follow-up periods. The average duration of response was 149 days for group A-2, and 187 days for group B. A majority of responders (11/19; 58%) were still responsive at the end of the current follow-up.

CONCLUSIONS:

The responses observed may be significant and relatively durable. This study suggests that DC-based cancer vaccines in the future may provide an additional therapy for advanced prostate cancer.

• Authors: B A Tjoa, S J Simmons, A Elgamal, M Rogers, H Ragde, G M Kenny, M J Troychak, A L Boynton, G P Murphy
• Journal: The Prostate (Prostate) Vol. 40 Issue 2 Pg. 125-9 (Jul 01 1999) ISSN: 0270-4137 [Print] United States
• PMID: 10386473 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antigens, Surface
• Cancer Vaccines
• HLA-A2 Antigen
• Carboxypeptidases
• FOLH1 protein, human
• Glutamate Carboxypeptidase II
• Prostate-Specific Antigen

Topics

• Antigens, Surface
• Cancer Vaccines (therapeutic use)
• Carboxypeptidases (immunology)
• Dendritic Cells (immunology)
• Glutamate Carboxypeptidase II
• HLA-A2 Antigen (immunology)
• Humans
• Immunotherapy
• Immunotherapy, Adoptive
• Leukapheresis
• Male
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms (immunology, therapy)